First human test of gene injection aims to halt blinding eye disease

NCT ID NCT03846193

Terminated Disease control Sponsor: Gyroscope Therapeutics Limited Source: ClinicalTrials.gov ↗

Summary

This early-stage study tested a new gene therapy called GT005 for people with an advanced form of dry age-related macular degeneration (AMD) that causes vision loss. The therapy involved a single injection into the back of the eye, aiming to deliver a gene that might help control the disease. The main goals were to check the safety of the treatment and see if it could slow the progression of vision loss.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Locations

Bristol Eye Hospital

Bristol, United Kingdom
Cincinnati Eye Institute

Cincinnati, Ohio, 45242, United States
Manchester Eye Hospital

Manchester, United Kingdom
Mid-Atlantic Retina

Philadelphia, Pennsylvania, 19107, United States
Midwest Eye Institute

Indianapolis, Indiana, 46290, United States
Moorfields Eye Hospital

London, United Kingdom
Ophthalamic Consultants of Boston (OCB)

Boston, Massachusetts, 02114, United States
Oxford University Hospital

Oxford, United Kingdom
Pepose Vision Institute

Chesterfield, Missouri, 63017, United States
Retina Clinic London

London, W1G 7LA, United Kingdom
Sierra Eye Associates

Reno, Nevada, 89502, United States
Sunderland Eye Infirmary

Sunderland, United Kingdom
Wolfe Eye Clinic

West Des Moines, Iowa, 50266, United States

Conditions

Explore the condition pages connected to this study.